Clinical Trials Browser

Phase 1/2 × rovalpituzumab tesirine × Dermatologic × Clear all

NCT02709889 2020-10-19

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

Phase 1/2 Terminated

200 enrolled 21 charts

CNSDermatologic

Glioblastoma, Melanoma, Carcinoma, Medullary